SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Peng, X ^a   Xie, G ^a   Wang, Z ^a   Lin, H ^a   Zhou, T ^a   Xiang, P ^a   Jiang, Y ^a   Yang, S ^a   Wei, Y ^a   Yu, L ^a   Zhao, Y ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Benzothiazole 2 thiol derivative; Cancer; Proliferation; RhoGDI

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTHIAZOLE 2 THIOL DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; SKLB 163; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; BENZOTHIAZOLE; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; SKLB-163; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MASS SPECTROMETRY; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOTHIAZOLES; CASPASE 3; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME ACTIVATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MASS SPECTROMETRY; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 8; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; RHO-SPECIFIC GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS;

EID: 84897448414     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.107     Document Type: Article

References (22)

1. Varmus H. The new era in cancer research. Science 2006; 312: 1162-1165.
2. Hawk E, Viner JL. What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment. Semin Oncol 2006; 33(6 Suppl 11): S6-S9.
3. Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. OncoTargets Therapy 2013; 6: 563-576.
4. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.
5. Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD et al. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 2001; 44: 1446-1455.
6. Kok SH, Gambari R, Chui CH, Yuen MC, Lin E, Wong RS et al. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg Med Chem 2008; 16: 3626-3631.
7. Trapani G, Franco M, Latrofa A, Reho A, Liso G. Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b] benzothiazoles. Eur J Pharmaceut Sci 2001; 14: 209-216.
8. Song EY, Kaur N, Park MY, Jin Y, Lee K, Kim G et al. Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur J Med Chem 2008; 43: 1519-1524.
9. Srimanth K, Rao VR, Krishna DR. Synthesis and evaluation of anticancer activity of some imidazothiazolyl, imidazobenzothiazolyl and dihydroimidazothiazolyl coumarins. Arzneimittel- Forschung 2002; 52: 388-392.
10. Wang Z, Shi XH, Wang J, Zhou T, Xu YZ, Huang TT et al. Synthesis, structure-activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers. Bioorg Med Chem Lett 2011; 21: 1097-1101.
11. Park YJ, Ahn HJ, Chang HK, Kim JY, Huh KH, Kim MS et al. The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line. Cell Signal 2009; 21: 356-364.
12. Shigetomi H, Higashiura Y, Kajihara H, Kobayashi H. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review). Oncol Rep 2012; 28: 395-408.
13. Novello S, Giaj Levra M, Vavala T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. Crit Rev Oncol Hematol 2012; 83: 208-215.
14. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999; 11: 545-554.
15. Sasaki T, Takai Y. The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control. Biochem Biophys Res Commun 1998; 245: 641-645.
16. Golovanov AP, Chuang TH, DerMardirossian C, Barsukov I, Hawkins D, Badii R et al. Structure-activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. J Mol Biol 2001; 305: 121-135.
17. Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 2005; 65: 6054-6062.
18. Poland J, Schadendorf D, Lage H, Schnolzer M, Celis JE, Sinha P. Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med 2002; 40: 221-234.
19. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using twodimensional electrophoresis. Electrophoresis 2000; 21: 3048-3057.
20. Zhao L, Wang H, Li J, Liu Y, Ding Y. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. J Proteome Res 2008; 7: 3994-4003.
21. Wang X, Wei Y, Yuan S, Liu G, Zhang YL, Wang W. Potential anticancer activity of litchi fruit pericarp extract against hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2006; 239: 144-150.
22. Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One 2011; 6: e27309.